Lakefront Biotherapeutics buys back €2.85M in shares

Lakefront held 1,985,157 of its own ordinary shares as of October 16, 2026, after completing the repurchase program.

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV repurchased 107,804 shares between October 12 and October 16, 2026, for a total of €2,854,365.69 at an average price of €26.48 per share. The purchases were made through a discretionary mandate to an independent financial intermediary.

As of market close on October 16, 2026, Lakefront held 1,985,157 of its own ordinary shares. The repurchase program announced on June 9, 2026, was fully completed.

Key Figures

Shares repurchased: 107,804 shares Total purchase amount: €2,854,365.69 Average price paid: €26.48 per share +1 more

4 metrics

Shares repurchased 107,804 shares Between October 12 and October 16, 2026

Total purchase amount €2,854,365.69 Repurchases between October 12 and October 16, 2026

Average price paid €26.48 per share Repurchases between October 12 and October 16, 2026

Own ordinary shares held 1,985,157 shares As of market close on October 16, 2026

Key Terms

discretionary mandate, ordinary shares, forward-looking statements

3 terms

discretionary mandate financial

"via a discretionary mandate to an independent financial intermediary"

ordinary shares financial

"Lakefront holds 1,985,157 of its own ordinary shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

forward-looking statements regulatory

"This press release contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did LKFT repurchase, and at what average price?

Lakefront repurchased 107,804 shares at an average price of €26.48 per share between October 12 and October 16, 2026.

How much did LKFT pay for the repurchased shares?

Lakefront reported a total purchase amount of €2,854,365.69 for the 107,804 shares repurchased between October 12 and October 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:37 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:36 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On October 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated October 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Lakefront Biotherapeutics
		(Registrant)
Date: October 20, 2026		/s/ Ying Deng
		Ying Deng
		Authorized Officer

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 12, 2026, and October 16, 2026, it has repurchased 107,804 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase	Market/MTF	Number of shares	Average price paid (€)	Total (€)	Lowest price paid (€)	Highest price paid (€)
10/12/2026	XAMS	20,818	26.51	551,843.54	26.38	26.68
10/12/2026	CEUX	4,350	26.56	115,543.40	26.44	26.68
10/12/2026	AQEU	429	26.55	11,391.15	26.44	26.58
10/12/2026	TQEX	186	26.53	4,935.12	26.44	26.62
10/13/2026	XAMS	20,811	26.36	548,480.15	26.16	26.52
10/13/2026	CEUX	2,446	26.41	64,590.05	26.30	26.50
10/13/2026	AQEU	1,896	26.41	50,081.13	26.30	26.52
10/13/2026	TQEX	634	26.37	16,717.06	26.30	26.46
10/15/2026	XAMS	23,113	26.49	612,304.97	26.04	26.98
10/15/2026	CEUX	3,219	26.26	84,545.75	26.14	26.92
10/15/2026	AQEU	1,520	26.22	39,859.26	26.16	26.88
10/15/2026	TQEX	333	26.13	8,701.02	26.12	26.30
10/16/2026	XAMS	24,946	26.57	662,730.40	26.18	26.76
10/16/2026	CEUX	2,287	26.63	60,909.67	26.28	26.78
10/16/2026	AQEU	65	26.46	1,719.90	26.46	26.46
10/16/2026	TQEX	751	26.65	20,013.10	26.40	26.80
Total		107,804	26.48	2,854,365.69	26.04	26.98

As of market close on October 16, 2026, Lakefront holds 1,985,157 of its own ordinary shares.

With these purchases, the repurchase program announced on June 9, 2026, has been fully completed.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 34.4 KB